Efficacy of High-Dose Trimethoprim-Sulfamethoxazol Prophylaxis on Early Urinary Tract Infection After Renal Transplantation

H. T. Khosroshahi, A. N. Mogaddam, Mohammadali Mohajel Shoja

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Urinary tract infection (UTI), a major cause of morbidity in renal transplant recipients, has also been found to increase mortality. The first month post-kidney transplantation is considered the critical time, with most UTI episodes during this period. The aim of this study was to compare the efficacy of various doses of trimethoprim-sulfamethoxazole (TMP/SXT) for the prophylaxis of the posttransplant UTI within the first month after kidney transplantation. In a prospective, double-blind, randomized, clinical trial, 95 kidney allograft recipients were divided into two groups: group 1 (n = 63) received low to moderate doses of TMP/SXT (either 80/400 mg or 160/800 mg, daily) and group 2 (n = 32), high doses of TMP/SXT (320/1600 mg, daily in two divided doses). These groups were comparable regarding age, gender, type of donor, and ureteral anastomosis and immunosuppressive therapy. UTI was defined as a urine culture containing more than 105 colonies. The mean age of the patients was 37 ± 12.2 years with a male/female ratio of 0.98/1. The urine culture was positive in 39 patients (41.1%). UTI was more common among female than male patients (P = .003). Escherichia coli was the most common isolated organism in both groups (53.8%). UTI was observed in about 25% of patients on the high-dose versus 49.2% of those on low- to moderate-dose prophylaxis (P < .05). In conclusion, prophylaxis with high-dose TMP/SXT (320/1600 mg, daily) is preferred for renal transplant recipients during the first month posttransplantation.

Original languageEnglish (US)
Pages (from-to)2062-2064
Number of pages3
JournalTransplantation Proceedings
Volume38
Issue number7
DOIs
StatePublished - Sep 1 2006
Externally publishedYes

Fingerprint

Trimethoprim
Urinary Tract Infections
Kidney Transplantation
Thymidine Monophosphate
Kidney
Urine
Sulfamethoxazole Drug Combination Trimethoprim
Immunosuppressive Agents
Allografts
Randomized Controlled Trials
Tissue Donors
Escherichia coli
Morbidity
Mortality

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Efficacy of High-Dose Trimethoprim-Sulfamethoxazol Prophylaxis on Early Urinary Tract Infection After Renal Transplantation. / Khosroshahi, H. T.; Mogaddam, A. N.; Mohajel Shoja, Mohammadali.

In: Transplantation Proceedings, Vol. 38, No. 7, 01.09.2006, p. 2062-2064.

Research output: Contribution to journalArticle

Khosroshahi, H. T. ; Mogaddam, A. N. ; Mohajel Shoja, Mohammadali. / Efficacy of High-Dose Trimethoprim-Sulfamethoxazol Prophylaxis on Early Urinary Tract Infection After Renal Transplantation. In: Transplantation Proceedings. 2006 ; Vol. 38, No. 7. pp. 2062-2064.
@article{83ff2061e7834e3096ccb012175a5e8b,
title = "Efficacy of High-Dose Trimethoprim-Sulfamethoxazol Prophylaxis on Early Urinary Tract Infection After Renal Transplantation",
abstract = "Urinary tract infection (UTI), a major cause of morbidity in renal transplant recipients, has also been found to increase mortality. The first month post-kidney transplantation is considered the critical time, with most UTI episodes during this period. The aim of this study was to compare the efficacy of various doses of trimethoprim-sulfamethoxazole (TMP/SXT) for the prophylaxis of the posttransplant UTI within the first month after kidney transplantation. In a prospective, double-blind, randomized, clinical trial, 95 kidney allograft recipients were divided into two groups: group 1 (n = 63) received low to moderate doses of TMP/SXT (either 80/400 mg or 160/800 mg, daily) and group 2 (n = 32), high doses of TMP/SXT (320/1600 mg, daily in two divided doses). These groups were comparable regarding age, gender, type of donor, and ureteral anastomosis and immunosuppressive therapy. UTI was defined as a urine culture containing more than 105 colonies. The mean age of the patients was 37 ± 12.2 years with a male/female ratio of 0.98/1. The urine culture was positive in 39 patients (41.1{\%}). UTI was more common among female than male patients (P = .003). Escherichia coli was the most common isolated organism in both groups (53.8{\%}). UTI was observed in about 25{\%} of patients on the high-dose versus 49.2{\%} of those on low- to moderate-dose prophylaxis (P < .05). In conclusion, prophylaxis with high-dose TMP/SXT (320/1600 mg, daily) is preferred for renal transplant recipients during the first month posttransplantation.",
author = "Khosroshahi, {H. T.} and Mogaddam, {A. N.} and {Mohajel Shoja}, Mohammadali",
year = "2006",
month = "9",
day = "1",
doi = "10.1016/j.transproceed.2006.06.111",
language = "English (US)",
volume = "38",
pages = "2062--2064",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "7",

}

TY - JOUR

T1 - Efficacy of High-Dose Trimethoprim-Sulfamethoxazol Prophylaxis on Early Urinary Tract Infection After Renal Transplantation

AU - Khosroshahi, H. T.

AU - Mogaddam, A. N.

AU - Mohajel Shoja, Mohammadali

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Urinary tract infection (UTI), a major cause of morbidity in renal transplant recipients, has also been found to increase mortality. The first month post-kidney transplantation is considered the critical time, with most UTI episodes during this period. The aim of this study was to compare the efficacy of various doses of trimethoprim-sulfamethoxazole (TMP/SXT) for the prophylaxis of the posttransplant UTI within the first month after kidney transplantation. In a prospective, double-blind, randomized, clinical trial, 95 kidney allograft recipients were divided into two groups: group 1 (n = 63) received low to moderate doses of TMP/SXT (either 80/400 mg or 160/800 mg, daily) and group 2 (n = 32), high doses of TMP/SXT (320/1600 mg, daily in two divided doses). These groups were comparable regarding age, gender, type of donor, and ureteral anastomosis and immunosuppressive therapy. UTI was defined as a urine culture containing more than 105 colonies. The mean age of the patients was 37 ± 12.2 years with a male/female ratio of 0.98/1. The urine culture was positive in 39 patients (41.1%). UTI was more common among female than male patients (P = .003). Escherichia coli was the most common isolated organism in both groups (53.8%). UTI was observed in about 25% of patients on the high-dose versus 49.2% of those on low- to moderate-dose prophylaxis (P < .05). In conclusion, prophylaxis with high-dose TMP/SXT (320/1600 mg, daily) is preferred for renal transplant recipients during the first month posttransplantation.

AB - Urinary tract infection (UTI), a major cause of morbidity in renal transplant recipients, has also been found to increase mortality. The first month post-kidney transplantation is considered the critical time, with most UTI episodes during this period. The aim of this study was to compare the efficacy of various doses of trimethoprim-sulfamethoxazole (TMP/SXT) for the prophylaxis of the posttransplant UTI within the first month after kidney transplantation. In a prospective, double-blind, randomized, clinical trial, 95 kidney allograft recipients were divided into two groups: group 1 (n = 63) received low to moderate doses of TMP/SXT (either 80/400 mg or 160/800 mg, daily) and group 2 (n = 32), high doses of TMP/SXT (320/1600 mg, daily in two divided doses). These groups were comparable regarding age, gender, type of donor, and ureteral anastomosis and immunosuppressive therapy. UTI was defined as a urine culture containing more than 105 colonies. The mean age of the patients was 37 ± 12.2 years with a male/female ratio of 0.98/1. The urine culture was positive in 39 patients (41.1%). UTI was more common among female than male patients (P = .003). Escherichia coli was the most common isolated organism in both groups (53.8%). UTI was observed in about 25% of patients on the high-dose versus 49.2% of those on low- to moderate-dose prophylaxis (P < .05). In conclusion, prophylaxis with high-dose TMP/SXT (320/1600 mg, daily) is preferred for renal transplant recipients during the first month posttransplantation.

UR - http://www.scopus.com/inward/record.url?scp=33846047391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846047391&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2006.06.111

DO - 10.1016/j.transproceed.2006.06.111

M3 - Article

VL - 38

SP - 2062

EP - 2064

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 7

ER -